Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Neutral 47.8%

Neg 0% Neu 47.8% Pos 0%

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $170 to $100.